Crizanlizumab for Treating COVID-19 Vasculopathy (CRITICAL)
Sponsor: Brigham and Women's Hospital
Listed as NCT04435184, this PHASE2 trial focuses on COVID-19 and remains completed. Sponsored by Brigham and Women's Hospital, it has been updated 9 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2021 — Dec 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Brigham and Women's Hospital
- Johns Hopkins University
- Novartis
- Socar Research SA
For direct contact, visit the study record on ClinicalTrials.gov .